InSphero, NCATS to Present Collaborative Research at SLAS2016
News Jan 26, 2016
InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologie transfer GmbH, at the annual meeting of the Society for Laboratory Automation and Screening (SLAS) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens M. Kelm during Monday afternoon’s Assay Development & Screening poster session.
InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating highly biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than traditional 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines with stromal fibroblasts were generated using InSphero’s patented hanging drop technology. Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration confirmed more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues than to the same cells grown in monolayer. Furthermore, the screen identified three compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking heterogeneous tumor microenvironments when conducting such high-throughput in vitro screens.
Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens. “Here we’ve established a multi-parametric phenotypic screening method that not only factors in tumor size and cell viability, but also discriminates between anti-tumor and non-specific toxic effects of compounds. Using these results, we can determine a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.”
In addition to Dr. Kelm’s poster presentation, InSphero microtissues and high-throughput screening and imaging concepts will be featured during several events at SLAS2016, including two exhibitor tutorials and other collaborative posters.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019